Skip to content

Study · Case report or series · n = 1 · 2025

3 results

Worsening vasomotor symptoms in the setting of estradiol and semaglutide: a case report.

Parker AE

Menopause (New York, N.Y.)1 Dec 2025Cited by 1 (Europe PMC)

PMID40729307 (opens in a new tab)DOI10.1097/gme.0000000000002621 (opens in a new tab)PepBankPUB-40729307
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 51-year-old postmenopausal woman taking oral estrogen, vasomotor symptoms increased in incidence and intensity during semaglutide dose titration.

    In plain wordsIn one postmenopausal woman on oral estrogen, hot-flush type symptoms got worse while her semaglutide dose was being raised.

    Peptide
    Semaglutide
    Outcome
    IncreaseVasomotor symptoms during dose titration
    Study

    n = 1

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    During the semaglutide dose titration, the patient experienced changes in mood as well as increased incidence and intensity of vasomotor symptoms.
    1 context sentence
    Summary · context
    A case is reported of a 51-year-old postmenopausal female prescribed oral estrogen for the treatment of vasomotor symptoms of menopause.
  2. 02HumanCase report or seriesSafety outcome

    In a 51-year-old postmenopausal woman taking oral estrogen, mood changes occurred during semaglutide dose titration.

    In plain wordsIn one postmenopausal woman on oral estrogen, mood changes appeared while her semaglutide dose was being raised.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedMood changes during dose titration
    Study

    n = 1

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    During the semaglutide dose titration, the patient experienced changes in mood as well as increased incidence and intensity of vasomotor symptoms.
    1 context sentence
    Summary · context
    A case is reported of a 51-year-old postmenopausal female prescribed oral estrogen for the treatment of vasomotor symptoms of menopause.
  3. 03HumanCase report or seriesSafety outcome

    In the same patient, slowing semaglutide dose titration was followed by resolution of the mood changes and vasomotor symptoms.

    In plain wordsIn this one patient, slowing the semaglutide dose increase was followed by the mood changes and vasomotor symptoms going away.

    Peptide
    Semaglutide
    Outcome
    DecreaseResolution of symptoms after slower titration
    Study

    n = 1

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The patient's semaglutide dose titration was slowed with subsequent resolution of mood changes and vasomotor symptoms.
    1 context sentence
    Summary · context
    A case is reported of a 51-year-old postmenopausal female prescribed oral estrogen for the treatment of vasomotor symptoms of menopause.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.